Core Insights - Alumis Inc. reported positive Phase 3 topline results for envudeucitinib, showing significant skin clearance and symptom improvement in moderate-to-severe plaque psoriasis, along with a favorable safety profile [1][2] - The company plans to submit a New Drug Application (NDA) for envudeucitinib in the second half of 2026 [1] - Anticipated pivotal Phase 2b clinical data for envudeucitinib in systemic lupus erythematosus (SLE) is expected in the third quarter of 2026 [1][7] - Alumis completed a public offering, raising approximately $345.1 million in gross proceeds in January 2026 [1][5] Phase 3 Clinical Trials - The Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib met all primary and secondary endpoints with high statistical significance [5] - Approximately 65% of patients achieved a Psoriasis Area Severity Index (PASI) 90, and over 40% achieved PASI 100 at Week 24 [5] - The drug demonstrated a favorable safety and tolerability profile consistent with earlier Phase 2 results [5] Financial Performance - For the year ended December 31, 2025, Alumis reported total revenue of $24.05 million, primarily from license and collaboration revenue [15] - Research and development expenses increased to $386.0 million from $265.6 million in 2024, driven by clinical trial costs and increased headcount [12][15] - The net loss for 2025 was $243.3 million, an improvement from a net loss of $294.2 million in 2024 [12][15] Pipeline and Future Plans - Alumis is evaluating additional indications for envudeucitinib beyond psoriasis and SLE, as part of a unified TYK2 franchise development strategy [2][5] - An update on the TYK2 franchise strategy, including the timing for commencing A-005's Phase 2 trial, is expected in the second quarter of 2026 [5][8] - The company plans to present additional Phase 3 data at the American Academy of Dermatology (AAD) Annual Meeting in March 2026 [11]

Core Insights - BML Capital Management has completely liquidated its stake in Alumis, selling 1,210,415 shares for approximately $4.83 million, resulting in a total position value decrease in Alumis [1][2] Company Overview - Alumis is a clinical-stage biotechnology company focused on developing therapies for autoimmune and neuroinflammatory diseases, leveraging TYK2 inhibition to create differentiated drug candidates [6][9] - The company has a market capitalization of $3.3 billion, with a revenue of $22.12 million and a net income of -$245.15 million for the trailing twelve months [4] Stock Performance - As of February 2, shares of Alumis were priced at $26.42, reflecting a 255.1% increase over the previous year, significantly outperforming the S&P 500's approximate 15% gain during the same period [3] Financial Context - The decision to sell was made before Alumis announced a public offering in January, which subsequently led to a surge in share price by roughly 200% [10] - The company reported $377.7 million in cash and marketable securities as of the third quarter, indicating a need for substantial funding to advance its TYK2 inhibitor programs [11] Market Dynamics - The market's reaction to the January offering shifted the narrative from capital risk to clinical optionality, leading to a rapid repricing of the stock [12] - The exit from Alumis by BML Capital was more about exposure control rather than a negative assessment of the company's scientific prospects [12]

Summary of Alumis Conference Call Company Overview - **Company**: Alumis - **Lead Candidate**: Nvudusitinib, a next-generation TYK2 inhibitor - **Focus**: Treatment of moderate to severe plaque psoriasis and potential applications in other immune-mediated diseases Key Points from the Call Clinical Results - **Phase 3 Results**: Positive outcomes for Nvudusitinib, exceeding Phase 2 results with statistically significant efficacy on primary and secondary endpoints [4][5] - **Efficacy Metrics**: - 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at week 16 [12] - Approximately 65% achieved PASI 90 and over 40% achieved PASI 100 at week 24 [12] - **Safety Profile**: Favorable safety and tolerability consistent with Phase 2 data, with most adverse events being mild to moderate [13] Market Opportunity - **Psoriasis Market**: Expected to reach $40 billion by 2030, with many patients currently underserved [6] - **Treatment Landscape**: Less than 20% of patients receive systemic treatment, and only 8% are treated with high-efficacy drugs [21] - **Patient Preferences**: 75% of patients prefer oral therapies over biologics, highlighting the demand for convenient treatment options [24] Future Developments - **NDA Filing**: Anticipated in the second half of 2026, pending data from the randomized withdrawal portion of the Phase 3 trial [37] - **Additional Trials**: Plans for a pivotal Phase 2b trial in systemic lupus erythematosus (SLE) with top-line data expected in Q3 2026 [6][28] - **Pipeline Expansion**: Development of A005, a CNS-penetrant TYK2 inhibitor, with a Phase 2 trial in multiple sclerosis planned for the first half of the year [27] Competitive Landscape - **Comparison with Competitors**: Nvudusitinib shows competitive efficacy compared to other oral therapies, including Icotrokinra and Apremilast [32][50] - **Mechanism of Action**: TYK2 inhibition may provide additional benefits beyond IL-23 and IL-17 pathways, particularly in itch reduction [51] Strategic Insights - **Market Positioning**: Alumis aims to position Nvudusitinib as a leading oral therapy for psoriasis, addressing significant unmet needs in the market [20][25] - **Partnership Considerations**: The company is evaluating strategic partnerships to maximize the asset's value, particularly in light of its broad potential across multiple indications [54] Additional Considerations - **Patient-Reported Outcomes**: Improvements in quality of life and itch were noted, which are critical factors for patient satisfaction [5][19] - **Regulatory Strategy**: Ongoing discussions with the FDA regarding the NDA filing and statistical analysis plans [38] Conclusion - **Outlook for 2026**: Alumis anticipates significant value inflection with the advancement of Nvudusitinib and its broader pipeline, aiming to address the substantial unmet needs in the treatment of psoriasis and other immune-mediated diseases [77]

Core Insights - Alumis Inc. announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, a selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis [2][3] - The trials met all primary and secondary endpoints with high statistical significance, showing superior skin clearance compared to placebo [3][4] - Approximately 65% of patients achieved PASI 90 and over 40% achieved PASI 100 at Week 24, indicating strong efficacy [4] Clinical Trial Results - Envudeucitinib achieved PASI 75 in 74% of patients and sPGA 0/1 in 59% of patients at Week 16, with rapid responses observed as early as Week 4 [3][4] - The drug demonstrated a favorable safety profile, with treatment-emergent adverse events primarily mild to moderate [5] - No new safety signals were reported, and common adverse events included headaches and upper respiratory infections [5] Future Plans - Alumis plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026 [2][6] - Additional results from the ONWARD trials will be presented at an upcoming medical meeting [6] - Topline data from the LUMUS Phase 2b trial in systemic lupus erythematosus is expected in Q3 2026 [7] Company Overview - Alumis is focused on developing next-generation targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [13] - The company is also developing other therapies, including A-005 for neuroinflammatory diseases and lonigutamab for thyroid eye disease [13] - The potential of envudeucitinib is highlighted as a transformative option for treating IL-23/IL-17-driven diseases [6][10]